Brokerages expect Bio-Path Holdings Inc (NASDAQ:BPTH) to post ($0.67) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Bio-Path’s earnings. Bio-Path posted earnings per share of ($0.89) during the same quarter last year, which indicates a positive year over year growth rate of 24.7%. The company is expected to report its next quarterly earnings results on Thursday, May 21st.
On average, analysts expect that Bio-Path will report full year earnings of ($2.67) per share for the current year. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover Bio-Path.
Bio-Path (NASDAQ:BPTH) last announced its quarterly earnings results on Friday, March 6th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.03).
An institutional investor recently raised its position in Bio-Path stock. Bank of Montreal Can lifted its stake in Bio-Path Holdings Inc (NASDAQ:BPTH) by 211.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,010 shares of the company’s stock after purchasing an additional 6,800 shares during the period. Bank of Montreal Can owned 0.35% of Bio-Path worth $80,000 as of its most recent SEC filing. Institutional investors own 7.12% of the company’s stock.
Bio-Path stock traded up $0.10 during trading hours on Monday, reaching $3.83. The stock had a trading volume of 68,400 shares, compared to its average volume of 99,978. The stock has a market cap of $14.02 million, a PE ratio of -1.17 and a beta of 3.15. Bio-Path has a 52 week low of $2.92 and a 52 week high of $24.73. The company has a debt-to-equity ratio of 0.02, a current ratio of 17.68 and a quick ratio of 17.68. The company has a fifty day simple moving average of $5.29 and a 200-day simple moving average of $8.15.
Bio-Path Company Profile
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Featured Article: Marijuana Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.